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i“It is much more important to know what sort
of a patient has a disease than what sort
of a disease a patient has.”
—William Osler (1)
Age-Associated Epidemic of Cardiovascular
Disease (CVD)
As the world’s population lives longer, CVD
evolves as the number one cause of disability and
death (2). CVD currently accounts for approxi-
mately 45% of all deaths in persons age 85 years and
older.
See page 234
Limited Success
The incidence of CVD and 50% 5-year mortality
rate of heart failure have remained unchanged for
2 decades (3). If the progression of CVD is not
substantially prevented, the epidemic will expand
and increasingly compromise the world’s health care
resources and quality of life.
Physiological Versus Chronologic Age
Chronologic age and physiological age are rarely in
sync. The “aging process” alters the substrate on
which specific pathophysiological disease mecha-
nisms become superimposed (4). There is a contin-
uum of expression of cardiac structural and func-
tional alterations that occurs with age in healthy
humans, and these age-associated cardiovascular
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vascular Imaging or the American College of Cardiology.
From the Mayo Clinic (Emeritus Nasseff Professor of Cardiology),
EchoMetrics Clinical Cardiologists, Inc., and Cardiovascular Decision,c
LLC, Rochester, Minnesota. Dr. Seward has reported that he has no
relationships to disclose.hanges seem to have relevance to the steep increase
n age-associated CVD (5). Chronologic age can
efine probable risk on the basis of expected pro-
rammatic change of natural markers (6). However,
ndividuals will physiologically age differently
ithin any peer group. The elapsed time since birth
s not an effective measure of functional age. At-
empts to manage a risk factor without defining and
ddressing the physiological substrate substantially
ontribute to the seemingly paradoxical outcomes in
linical trials (7). Prediction models, particularly
hose dependent on chronologic age, often do not
dequately characterize disease severity.
In this issue of iJACC, Boyd et al. (8) aptly show
hat echo/Doppler features can be used to assess the
hysiological status into the eighth decade. Al-
hough the authors focus on left atrial size, they
onfirm that healthy living is best defined by a
hysiological profile as opposed to chronologic age.
hese observations increase our window of under-
tanding regarding echo/Doppler as a multifeature
iomarker capable of quantifying physiological age
s a surrogate marker of an individual’s health
tatus. Complex physiology is multivariable, and the
se of a single biomarker will rarely characterize the
hysiological state (e.g., an enlarged left atrium can
lso be associated with completely normal diastolic
hysiology as seen in athletes and patients with
hronic noncardiac disease) (9).
eﬁning Physiological Age
ntil recently, determining physiological age has
emained qualitative or based on individual or
isparate seromarkers or biomarkers. However,
VD is complex and composed of multiple inter-
onnected parts that, as a whole, exhibit 1 or more
roperties (behavior among the possible properties),
hich are not obvious from the properties of
ndividual features, complex risk factors, or overt
linical disease (9). Multivariate physiologic models
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244best provide quantifiable expression of physiological
age relative to one’s chronologic peers (10).
Prediction
There is considerable misuse of the term prediction.
The task today must transcend current reliance on
diagnostic and prognostic prediction and evolve a
new paradigm that focuses on physiological status
and therapeutic value, where value implies predic-
tion of improved clinical outcome at reduced cost
(11). We must insist that virtually all risk models be
shown to do what they are supposed to do—predict
the prevention of clinical disease. The ability to
predict or reclassify risk is beside the point. In the
long run, a far superior approach to controlling
complex cardiovascular disease will be prevention
rather than treatment. The most logical approach is
to use sets of highly associated data that replicate
the physiological status of the patient (e.g., a
quantifiable surrogate disease state) and then ran-
domize treatment or control based on normaliza-
tion of the surrogate profile. True surrogate status
of a test only occurs when a change in the putative
surrogate attributable to an intervention approxi-
mates a prediction of a change in the clinical end
point. A model dependent on immutable chrono-
logic age will not attain surrogate status. We must
search for better ways of identifying at-risk individ-
uals so aggressive preventive measures can be tar-
geted while sparing those who are at no or ex-
tremely low risk and avoid the cost and side effects
of unnecessary or potentially lifelong drug therapy.
Multiple mutable echo/Doppler morphologic and
physiological features (image biomarkers) have been
amply validated and related to disease cause and effect
(12–14). Cause-and-effect prediction models are as
reliable as, and typically more reliable than, human
experts (15). Although current risk models (e.g.,
Framingham Risk Score), biomarkers (e.g., C-reactive
protein and B-natriuretic peptide), and advanced im-
age technologies (e.g., coronary calcium score, carotid
intima-media thickness) provide statistically signifi-
cant risk prediction information, they add only modest
incremental value and are not sufficiently precise to
markedly improve clinical outcome (16). In addition,
the premise of evidence-based medicine is to apply
“average effects” to patients in prescribing treatments
and preventive therapies (11). It is important to realize
that tests that do not change disease management and
substantially affect patient outcome are ultimately
cost-ineffective. Valued prediction models ideallyshould be based on multiple quantitatively coded cues
(i.e., elegant multivariable surrogate models) (17).
Ideal Multivariable Biomarker
An echo/Doppler model based on measured fea-
tures fits the definition of an ideal multivariable
biomarker, which approaches the status of a surro-
gate model. Interconnecting features must have
close similarities to and most importantly obey the
same fundamental rules as the emergent disease.
Interrelated features more easily define the minimal
requirements that best display disease behavior
(intensity and response to treatment). Echo/
Doppler goes beyond merely predicting risk. Echo/
Doppler models can quantify the intensity of emer-
gent CVD risk and more importantly assist
prediction of clinical outcome (18).
The only economical means of containing an
epidemic is prevention, which obligates prediction
based on recognition, understanding, and quantifi-
cation of the underlying cause-and-effect features,
which are highly associated with an emergent con-
dition. The echo/Doppler physiologic model meets
most of the following ingredients: a collection of
interacting features that are closely related and/or
share various degrees of common information, in-
teract with one another in a way that changes both
and erases their dependence on initial conditions,
measures features that adapt in accordance with
changing performance, and helps define “open”
systems that can be influenced by its environment
or management.
Simple quantifiable features are easy to compre-
hend and comfortable in our minds. They remove
ambiguities and reinforce a sense of understanding.
An echo/Doppler surrogate model should be com-
posed of a small number of simple interrelated
numerical features that provide a method for antic-
ipating complex events (predict), measure the mag-
nitude of variance (quantify), and foster a more
rapid and logical response to management of risk
(prevention). Diseases are best defined as an inter-
connected network rather than a bag of indepen-
dent unrelated chemicals (seromarkers), genes, or
clustered risk factors.
Window of Opportunity
Despite the dazzling technical advances in cardiol-
ogy, risk factor reduction and disease prevention in
the aging population remain inadequate. There is
an urgent need to look through the haze and find a
reproducible means of elucidating the natural his-
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245tory, pathophysiology, and optimal diagnostic and
management strategy for common medical syn-
dromes. The benefits of estimating an individual’s
total physiological risk and treating accordingly are
2-fold. First is the direction of preventive efforts
toward those most likely to benefit. Second is the
reassurance and avoidance of side effects in low-risk
persons who will derive less benefit, which also has
economic implications. An opportune comprehen-
sive multivariable echo/Doppler test is capable of
rigorously defining pre-symptomatic CVD (10,12).
The transition from a subjective to objective
definition of physiological aging is a major step
forward. As Boyd et al. demonstrate (8), small
aggregates of highly related numerical data can be
transformed into quantitative surrogate models of
CVD. Surrogate end points are intended to predictand altered function are mediated by
age and diastolic function but not
1
1
1
1
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tion Writing Grois difficult to collect suitable data based on clinical
end points. Pre-emptive testing can provide infor-
mation about a person’s risk of a disorder develop-
ing and help with making decisions about medical
management. The best high-risk approach to CVD
evaluation and prevention lies in testing quantifiable
physiological risk. Guidelines from the American
Heart Association recommend CVD assessment
beginning at 40 years of age and repeated every 5
years (or more frequently if risk factors change)
(19). The most logical window of opportunity lies
in the use of echo/Doppler imaging as a robust
multivariable biomarker and the construction of
elegant surrogate disease models.
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